Human antibody specific to toxin produced from clostridium difficile, or antigen-binding fragment thereof
AssigneeEvec Inc.
InventorsKenzo Takada, Masahiro Watanabe, Takashi Torashima
Life of this patent
Estimating the term…
Abstract
The present invention provides novel human-derived monoclonal antibodies specifically binding to toxins produced by Clostridium difficile (toxin A and toxin B), respectively, and having excellent neutralizing activity, and antigen-binding fragments thereof. The present invention also provides a pharmaceutical composition for the treatment of Clostridium difficile infection comprising any of the antibodies or antigen-binding fragments thereof.
Claims23
An antibody capable of specifically binding to Clostridium difficile toxin A protein and neutralizing its biological activity, or an antigen-binding fragment thereof, comprising:
- (i)
- (a) heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
- 4 or an amino acid sequence deviated from the amino acid sequence of SEQ ID NO:
- 4 by deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues,
- (b) heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
- 5 or an amino acid sequence deviated from the amino acid sequence of SEQ ID NO:
- 5 by deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues, and
- (c) heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
- 6 or an amino acid sequence deviated from the amino acid sequence of SEQ ID NO:
- 6 by deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues;
- and
- (ii)
- (a) light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
- 10 or an amino acid sequence deviated from the amino acid sequence of SEQ ID NO:
- 10 by deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues,
- (b) light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
- 11 or an amino acid sequence deviated from the amino acid sequence of SEQ ID NO:
- 11 by deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues, and
- (c) light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
- 12 or an amino acid sequence deviated from the amino acid sequence of SEQ ID NO:
- 12 by deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues.
An antibody capable of specifically binding to Clostridium difficile toxin B protein and neutralizing its biological activity, or an antigen-binding fragment thereof, containing:
- (i)
- (a) heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
- 16 or an amino acid sequence deviated from the amino acid sequence of SEQ ID NO:
- 16 by deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues,
- (b) heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
- 17 or an amino acid sequence deviated from the amino acid sequence of SEQ ID NO:
- 17 by deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues, and
- (c) heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
- 18 or an amino acid sequence deviated from the amino acid sequence of SEQ ID NO:
- 18 by deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues;
- and
- (ii)
- (a) light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
- 22 or an amino acid sequence deviated from the amino acid sequence of SEQ ID NO:
- 22 by deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues,
- (b) light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
- 23 or an amino acid sequence deviated from the amino acid sequence of SEQ ID NO:
- 23 by deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues, and
- (c) light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
- 24 or an amino acid sequence deviated from the amino acid sequence of SEQ ID NO:
- 24 by deletion, substitution, insertion, and/or addition mutations of one to several amino acid residues.
Dependencies are inferred from the claim text.